Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting
The use of targeted therapeutics known as poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors in the management of ovarian cancer is currently transforming clinical practice. The PARP inhibitor rucaparib is indicated in the UK, European Union and the United States for use in the treatmen...
Main Authors: | Laura Tookman, Jonathan Krell, Baleseng Nkolobe, Laura Burley, Iain A. McNeish |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-05-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/1758835920921980 |
Similar Items
-
Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
by: Graziela Z. Dal Molin, et al.
Published: (2018-06-01) -
Emerging treatment options for ovarian cancer: focus on rucaparib
by: Mariappan L, et al.
Published: (2017-12-01) -
Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
by: Pearre DC, et al.
Published: (2018-11-01) -
Pre-clinical imaging evaluation of the PARP inhibitor rucaparib
by: Almeida, Gilberto Serrano de
Published: (2013) -
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
by: Olga Kondrashova, et al.
Published: (2018-09-01)